Atara Biotherapeutics Announces Third Quarter 2014

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Atara Biotherapeutics Announces Third Quarter 2014 Operating Results

BRISBANE, Calif., Nov. 12, 2014 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA ), a biopharmaceutical development company with a focus on innovative therapies for patients with debilitating diseases, today reported financial results for the third quarter and nine months ended September 30, 2014.

"Atara has made significant accomplishments this year," said Isaac Ciechanover, CEO of Atara. "This past quarter we continued to advance our lead program, PINTA 745, and initiated the trial of our second clinical program, STM 434. Additionally, we entered into an exclusive option agreement with Memorial Sloan Kettering Cancer Center for the development and commercialization of allogeneic T cell therapies for the treatment of certain cancers and persistent viral infections."

Third Quarter 2014 Financial Results

  • Atara reported a net loss of $5.9 million, or $4.20 per share, for the third quarter of 2014, compared to a net loss of $2.5 million, or $2.59 per share, for the third quarter of 2013.
     
  • Research and development expenses, including costs paid to Amgen, Inc., increased to $4.2 million for the third quarter of 2014, compared to $1.7 million for the third quarter of 2013, driven primarily by the option and related costs paid to Memorial Sloan Kettering Cancer Center in September 2014 and higher costs related to expanded clinical development activities and increased headcount.
     
  • General and administrative expenses increased to $1.7 million for the third quarter of 2014, compared to $0.9 million for the third quarter of 2013, primarily related to increased headcount and higher professional service fees.
     
  • Operating expenses as described above include non-cash stock-based compensation expense of $0.5 million for the third quarter of 2014, compared to $0.3 million for the third quarter of 2013.
     
  • As of September 30, 2014, Atara had approximately $51.7 million in cash and cash equivalents and short-term available-for-sale investments. This amount excludes $55.8 million of net proceeds from the sale of 5.8 million shares of common stock from Atara's initial public offering in October 2014.

About Atara

Atara Biotherapeutics, Inc. is a biopharmaceutical development company focusing on innovative therapies for patients with debilitating diseases. The company's lead programs are focused on myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of clinical indications.

 

 
ATARA BIOTHERAPEUTICS, INC.
Condensed Combined and Consolidated Balance Sheets
(Unaudited)
(In thousands, except share and per share amounts)
 
  September 30, December 31,
  2014 2013
Assets    
Current assets    
Cash and cash equivalents $ 25,703 $ 51,615
Short-term available-for-sale investments 25,996 —
Prepaid expenses and other current assets 323 193
Total current assets 52,022 51,808
Property and equipment, net 14 8
Other assets 2,084 12
Total assets $ 54,120 $ 51,828
Liabilities, convertible preferred stock and stockholders' deficit    
Current liabilities:    
Accounts payable $ 569 $ 606
Accrued compensation 500 331
Income tax payable 63 155
Other accrued liabilities 1,280 432
Total current liabilities 2,412 1,524
Other long-term liabilities 165 230
Total liabilities 2,577 1,754
Commitments and contingencies (Note 5)    
Series A convertible preferred stock—$0.0001 par value, liquidation preference of $20,088 19,909 19,909
Series A-1 convertible preferred stock—$0.0001 par value, liquidation preference of $3,000 2,768 2,768
Series B convertible preferred stock—$0.0001 par value, liquidation preference of $52,000 51,895 38,414
Stockholders' deficit    
Common stock—$0.0001 par value, 12,003,891 and 1,509,712 shares issued and outstanding as of December 31, 2013 and September 30, 2014, respectively — 1
Additional paid-in capital 7,344 2,200
Notes receivable from stockholder -- (335)
Accumulated other comprehensive loss (11) —
Accumulated deficit (30,362) (12,883)
Total stockholders' deficit (23,029) (11,017)
Total liabilities, convertible preferred stock and stockholders' deficit $ 54,120 $ 51,828

 

 
 
ATARA BIOTHERAPEUTICS, INC.
Condensed Combined and Consolidated Statements of Operations and Comprehensive Loss
(Unaudited)
(In thousands, except share and per share amounts)
 
  Three months ended Nine months ended
  September 30, September 30,
  2014 2013 2014 2013
Expenses:        
Research and development $ 4,241 $ 1,134 $ 9,332 $ 2,057
Research and development costs paid to Amgen — 550 1,066 550
General and administrative 1,708 868 7,162 2,591
Total operating expenses 5,949 2,552 17,560 5,198
Loss from operations (5,949) (2,552) (17,560) (5,198)
Interest income 30 3 59 8
Loss before provision for income taxes (5,919) (2,549) (17,501) (5,190)
Provision (benefit) for income taxes -- (13) (22) 27
Net loss $ (5,919) $ (2,536) $ (17,479) $ (5,217)
Other comprehensive loss, net of tax:        
Unrealized losses on investments (11) — (11) —
Other comprehensive loss (11) — (11) —
Comprehensive loss $ (5,930) $ (2,536) $ (17,490) $ (5,217)
Net loss per common share:        
Basic and diluted net loss per common share $ (4.20) $ (2.59) $ (13.07) $ (5.73)
Weighted-average common shares outstanding - basic and diluted 1,410,507 977,778 1,337,501 910,839

COMPANY CONTACT: Tina Gullotta 415-287-2427

Scroll down for more posts ▼

Top 10 Most Recent News Articles

BVM's Brookfield Headquarters Move Tests Growth Ambition

Updated Category News Views 13

A bigger office is rarely the exciting part of a growth story, yet it can reveal whether the machinery underneath is actually running hot. Best Version Media has moved its headquarters from Janacek Court to 15800 W. Bluemound Road, Suite 400, in Brookfield, Wisconsin, citing room for recent hires, future recruitment and closer collaboration across its print and digital...

Continue Reading
Insider Risk Makes Human Judgment a Security Priority

Updated Category News Views 145

A badge, a password, and a locked gate can all look reassuring right up until the person holding them starts to crack. Signpost Six's new report, The Psychology of Insider Risk, lands on an uncomfortable truth: the most consequential security weakness may not be a system at all. It may be an employee under strain, in conflict, in debt, making a mistake, or being quietly...

Continue Reading
Panama City Beach Rentals: Rules Before the Ocean View

Updated Category News Views 25

A postcard-perfect balcony can hide a remarkably expensive rulebook. That is the unglamorous message in Angie Outlaw’s discussion of vacation-property buying in Panama City Beach: the view may sell the unit, but zoning, association documents, insurance and lender terms determine whether the purchase behaves anything like the income-producing asset a buyer pictured. I...

Continue Reading
TRUSTA Targets AI Inference's GPU Memory Squeeze Hard

Updated Category News Views 103

GPU scarcity has turned ordinary server parts into strategic assets, and TRUSTA is leaning right into that uncomfortable fact at SuperComputing 2026. The enterprise-storage brand under ADATA is pitching an upgraded AI Scaler Toolkit built around a fairly sensible premise: companies running large-language-model inference should not have to buy another armful of expensive...

Continue Reading
Pacific Surfliner Faces Thanksgiving Capacity Test

Updated Category News Views 49

Thanksgiving traffic on Southern California freeways is its own yearly punishment, and the Pacific Surfliner is making a sensible pitch: leave the car parked and let the coast roll past the window. For travelers, that can be a real relief. For anyone watching public transportation, this is also a useful little stress test of whether a busy state-supported rail corridor...

Continue Reading
Rochester Truck Crashes Demand a Different Liability Map

Updated Category News Views 109

An 80,000-pound rig does not leave anybody the luxury of treating a wreck like a bent-fender dispute. That is the uncomfortable point behind Rochester attorney John Wright's discussion of truck crashes around I-390 and I-490. The physical damage may be obvious, but the legal story can be buried in dispatch systems, maintenance files, driver logs and corporate decisions...

Continue Reading
Snowrise Targets the Blind Spots in CPG Sales Data

Updated Category News Views 84

A sales total can look healthy while the floorboards are quietly rotting underneath it. That is the uncomfortable CPG problem Snowrise is aiming at: brands know what moved last quarter, but often cannot identify which stores, channels, communities, or promotions actually created the result. Plenty of management teams still steer by topline revenue, net distribution gains,...

Continue Reading
A €18 Million Mecca Chandelier Tests Austrian Craft

Updated Category News Views 171

Scale Is Easy to Boast About, Delivery Is Not A 34.1-metre chandelier hanging in Mecca is the sort of job that makes ordinary project talk sound downright silly. Lights of Vienna says it designed, built, tested, shipped and installed this monster for the Grand Mosque's Shamiya area, with a contract value of roughly €18 million. That is a serious piece of work for a...

Continue Reading
Kids First Data Sharing Raises Pediatric Research Bar

Updated Category News Views 73

Thirty-eight thousand children’s records are not a headline gimmick; they are a serious argument for treating research data as an asset that must keep working after the first study ends. The Gabriella Miller Kids First Data Resource Center’s ten-year review, published in the September 2026 issue of The American Journal of Human Genetics, makes that argument with...

Continue Reading
Markel's $2.5 Billion Buyback Adds Capital Flexibility

Updated Category News Views 37

A Large Checkbook, Not a Purchase Order Markel just handed management another $2.5 billion of repurchase firepower, and that deserves attention without the usual buyback cheerleading. The Board approved an increase to the existing authorization on November 18, 2026. That is a meaningful capital-allocation signal from a company built around specialty insurance,...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative Heart Device Developments: Anteris Reports Growth

Updated Category News Views 316

Focus on Innovative Heart Valve Technology Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR), a pioneering force in cardiac care, has made significant strides in Q1, showcasing its commitment to innovation in heart valve technology. The company, based in both Australia and the United States, is devoted to revolutionizing cardiac treatment through advanced device...

Continue Reading
X-Bow and AEON Forge Alliance for Tactical Missile Systems

Updated Category News Views 321

X-Bow and AEON Forge Alliance for Tactical Missile Systems X-Bow Systems Inc (NASDAQ: X-Bow), a pioneer in advanced solid rocket motors and defense technologies, has embarked on an exciting new journey. The company recently announced a strategic partnership with AEON Industrial Inc., a firm dedicated to developing innovative defense solutions. Together, they are set to...

Continue Reading
Exciting Developments Ahead for Apollo's Stockholders Meeting

Updated Category News Views 280

Apollo's Upcoming Annual Meeting of Stockholders Apollo, a leading asset management firm, is gearing up for its 2025 Annual Meeting of Stockholders. This highly anticipated event will be conducted virtually on June 6, 2025, starting at 9:30 am ET. Stockholders are encouraged to participate, as the meeting will provide a platform for key updates and insights from the...

Continue Reading
Navigating Challenges: John B. Sanfilippo & Son, Inc. Insights

Updated Category News Views 353

JBSS Stock Experiences Recent Low Amid Economic Changes As the market presents ongoing challenges for investors, John B. Sanfilippo & Son, Inc. (JBSS) has hit a new 52-week low, now trading at $88.55. This established company, recognized for its diverse nut and snack offerings, has seen a turbulent year in trading with a slight 1.27% decrease in value over the past year....

Continue Reading
AnswerRocket Enhances Analytics Platform with New AI Models

Updated Category News Views 168

AnswerRocket adds Gemini and Claude language models to boost analytics AnswerRocket is expanding its analytics platform with advanced language models, integrating the Gemini LLMs and the Anthropic Claude family. The goal is simple: give businesses real choice in how they work with data. With these options, teams can pick the model that best fits a given problem, rather...

Continue Reading